Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: AZILSARTAN: 40 MG, ORAL, ONCE A DAY, FOR 1 MONTH
Control Intervention1: BENIDIPINE: 4 MG, ORAL , ONCE A DAY, FOR 1 MONTH
Sponsors
Kasturba Medical College
Eligibility
Inclusion criteria
Inclusion criteria: Subjects, newly diagnosed with Essential Hypertension of Stage 1 with SBP ranging between 140-159 mmHg and/or DBP ranging between 90-99 mmHg as per JNC classification
Exclusion criteria
Exclusion criteria: 1) Subjects with secondary hypertension 2)Subjects with known CV risk factors, diabetes mellitus. 3)Subjects with any significant abnormalities on a 12-lead ECG 4)Subjects with known neuromuscular disorders 5)History of alcoholism (alcohol abuse) and cannot refrain from alcohol consumption during the study period. 6)History of smoking ( >1 pack per day or >20 cigarettes) and cannot refrain from smoking during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To evaluate and compare the effects on the arterial stiffness (AS) in newly diagnosed hypertensives being treated with either azilsartan or benidipineTimepoint: Two Followups for 3 and 6 months after being enrolled. Total duration for study - 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. To determine the factors contributing to the arterial stiffness. 3. To determine the prognostic value of non-invasive arterial stiffness assessment by pulse wave analysis automatic device Mobil-O-GraphÃ?® Timepoint: To be concluded by July 2020 | — |
Countries
India
Contacts
Public ContactDr Arthik M Shetty
Kasturba Medical College
Outcome results
None listed